The prequotation disclosure notice contains information that is required to be provided to ASX Limited (ASX) for release to the market in connection with the admission of the official list of, and official quotation of, fully paid ordinary shares in the Company.
View the Pre-Quotation Disclosure Notice.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)